Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane.

Yong EC, Chi EY, Fritsche TR, Henderson WR Jr.

J Exp Med. 1991 Jan 1;173(1):65-78.

2.

Two mechanisms for platelet-mediated killing of tumour cells: one cyclo-oxygenase dependent and the other nitric oxide dependent.

Okada M, Sagawa T, Tominaga A, Kodama T, Hitsumoto Y.

Immunology. 1996 Sep;89(1):158-64. Erratum in: Immunology 1997 May;91(1):159.

4.

Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.

Chang TS, Kim HM, Lee KS, Khil LY, Mar WC, Ryu CK, Moon CK.

Biochem Pharmacol. 1997 Jul 15;54(2):259-68.

PMID:
9271330
5.

Toxoplasma gondii stimulates the release of 13- and 9-hydroxyoctadecadienoic acids by human platelets.

Henderson WR Jr, Rashed M, Yong EC, Fritsche TR, Chiang GK.

Biochemistry. 1992 Jun 16;31(23):5356-62.

PMID:
1606159
6.

The role of thromboxane A2 in increased whole blood platelet aggregation in oral contraceptive users.

Norris LA, Devitt M, Bonnar J.

Thromb Res. 1996 Feb 15;81(4):407-17.

PMID:
8907290
7.

Human platelet inhibition of Toxoplasma gondii growth.

Chumpitazi BF, Simon J, Polack B, Peyron F, Picot S, Ricard J, Ambroise-Thomas P.

Clin Exp Immunol. 1998 Feb;111(2):325-33.

8.

Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2.

Caughey GE, Cleland LG, Gamble JR, James MJ.

J Biol Chem. 2001 Oct 12;276(41):37839-45. Epub 2001 Aug 1.

9.

Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.

Patscheke H, Stegmeier K.

Thromb Res. 1984 Feb 1;33(3):277-88.

PMID:
6424261
11.

Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.

Dorn GW 2nd, Burch RM, Kochel PJ, Mais DE, Halushka PV.

Biochem Pharmacol. 1987 Jun 15;36(12):1913-7.

PMID:
2954555
12.

Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.

Hirakata H, Ushikubi F, Toda H, Nakamura K, Sai S, Urabe N, Hatano Y, Narumiya S, Mori K.

Anesthesiology. 1996 Dec;85(6):1447-53.

PMID:
8968193
13.

Cytotoxic activity of 13-hydroxyoctadecadienoic acid against Toxoplasma gondii.

Henderson WR, Chi EY.

Parasitology. 1992 Dec;105 ( Pt 3):343-7.

PMID:
1461675
14.

Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.

Bureau MF, De Clerck F, Lefort J, Arreto CD, Vargaftig BB.

J Pharmacol Exp Ther. 1992 Feb;260(2):832-40.

PMID:
1738127
15.

Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery.

Pfister SL.

Hypertension. 2004 Feb;43(2):428-33. Epub 2004 Jan 12.

PMID:
14718367
17.

Abnormal platelet response to thromboxane A2.

Wu KK, Le Breton GC, Tai HH, Chen YC.

J Clin Invest. 1981 Jun;67(6):1801-4.

19.

Supplemental Content

Support Center